Founded in 2021, Laibo Ruichen is committed to the independent research and development and industrialization promotion of "First-in-Class" innovative drugs for bone and joint, and provides innovative treatment programs for the majority of bone and joint patients based on the unmet clinical drug demand in China and the world.